Compare Novartis AG (NVS) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Invesco S&P 500 Low Volatility ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Invesco S&P 500 Low Volatility ETF trades at $75.66. The key difference: Novartis AG pays a 3.17% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals.
| NVS | SPLV | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | — |
52-Week High | $168.62 | $77.45 |
52-Week Low | $113.50 | $70.30 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
SPLV trades at $76.09, down 0.63% on the day, with a bullish technical signal driven by moving averages. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market tensions. Recent news highlights its appeal as a defensive play during geopolitical and inflation concerns. Dividend payments of $0.14 per share are scheduled for mid-2026.
The outlook for SPLV is positive as a defensive equity holding, with low volatility strategies gaining traction in uncertain markets. Key risks include reliance on market volatility for relevance and potential underperformance in strong bull markets. Analyst sentiment is neutral to positive given current macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
